Close

Alnylam Pharma (ALNY) to Discontinue Development of Revusiran; Decision Will Not Affect Patisiran

October 5, 2016 4:31 PM EDT Send to a Friend
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced that upon the recommendation of the ENDEAVOUR Phase 3 study Data Monitoring Committee (DMC) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login